HTTIF.US HighTide Therapeutics, Inc.

Healthcare Biotechnology USA Stocks
0.3893 USD
Close of Nov 15, 2026
0.3499 0.4206
Market cap
USD 236M
P/E
-
P/B
9.50x
ROE
-75.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is HTTIF.US undervalued?

Graham number

The Graham number of HighTide Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

HighTide Therapeutics, Inc. fundamental analysis

No fundamental analysis for HighTide Therapeutics, Inc. yet.

HighTide Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About HighTide Therapeutics, Inc.

HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase I clinical trial to treat gradual loss of kidney function over time; phase IIb for the treatment of pathogenetic complexity and heterogeneity; phase I to treat obe…

Full company profile